PRIMA BIOMED REPORTS OVARIAN CANCER STUDY RESULTS

Prima BioMed has reported favorable results in its ongoing Phase IIa clinical trial in ovarian cancer.

Trial data has indicated that 21 percent of patients had achieved either a clinical response to treatment or stabilization of their disease. Patients in the study are late-stage progressive ovarian cancer patients with no therapeutic alternative. Fifteen per cent of patients having achieved either a clinical response to treatment or stabilization of their disease in the trial's patient population, for whom standard therapies provide minimal benefit, is considered a benchmark response rate to demonstrate that a therapy has sufficient activity to warrant its progression to a comparative clinical trial.